Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (603)	4/14/1997 12:35:00 PM
From: Peter Church	Respond to of 6136

Some results from scouting out Viracept's success: This from an AIDS Project affiliated with a hospital: Generally great success from PI's. Viracept appears to be the least toxic seen so far, but you can get non-detect with other drugs such as the cominations AZT and 3TC, or D4T and 3TC. These combos are even better tolerated than the PI's which are seen as the most potent. If your viral load is low and T-Cells are greater than 200, there is not much call for using a PI. This from Stadtlander's Rx ((800) 238-7828): Cost of Viracept is highest of the PI's at $557/mo. Crix is $495/mo. If you use a cocktail, the costs of each drug are added together at full strength. Viracept is used by people who have developed resistance to other drugs, but not normally for the first time PI user. I am not sure why not. Quit a few people are switching to Viracpet. Mild diarhea is the main problem. For anyone interested in this type of information, I recommend looking at a local equivalent to the SF Bay Times for HIV information centers and pharmacies. They have a wealth of first hand information available. Any comments on these qualitative data? Best regards---Peter

To: scaram(o)uche who wrote (603)	4/14/2006 1:49:54 PM
From: scaram(o)uche	Respond to of 6136

eximiaspharm.com Oncology is the area of medicine that studies the cause, diagnosis and treatment of cancer. Since 1990, more than 18,000,000 Americans have been diagnosed with some form of cancer. The American Cancer Society estimates over to 1.3 million Americans will be diagnosed with cancer in 2005. Over half a million cancer patients will die this year. Eximias’ lead oncology product, THYMITAQ® (nolatrexed), completed enrollment in a pivotal Phase III clinical trial for inoperable primary liver cancer (hepatocellular carcinoma or HCC) in April 2005. HCC is a rapidly fatal disease, and there is no FDA-approved treatment in the United States or in the European Union. In August 2005, the Company announced that the Phase III clinical study evaluating THYMITAQ® in patients with unresectable hepatocellular carcinoma (inoperable primary liver cancer) failed to achieve its primary endpoint, a survival benefit versus doxorubicin. Additional analyses have been conducted with the data from the Phase III study to better understand the results of the survival analysis and steer future activities.